The Pfizer Clinical Research Unit in New Haven is conducting a clinical trial of a study drug for specific tumors associated with cancer. This study will look at the effects of the study drug when single oral doses are given to healthy adults as a liquid or tablet, both with and without food.
The study drug in this trial is being evaluated together for the treatment of certain metastatic tumors (cancerous tumors that have spread from the original site to other places in the body). Cancer affects millions of people every year and is a leading cause of death worldwide. Despite modern advances in detection and available treatments, patients continue to face difficulties and need additional safe and effective options.
Learn how you can help patients as a healthy clinical trial volunteer below.
Who may participate
Every clinical trial is an important step on the path towards new medical discoveries, and trials are only made possible by participants.
This study is seeking healthy adult volunteers, meaning that the participants will not have the condition being studied and are in overall good health. In addition to the criteria listed, participants must meet the following requirements:
- Willing to take a study drug
- Willing and able to come to our facility in New Haven, CT*
- Willing and able to comply with all study procedures
*participants may be eligible to receive a bonus for travel, ask our staff for details
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Condition
Healthy
Age
18-60 years
Sex
All sexes
Referral bonus
Up to $200
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing.
If you choose to participate, you will stay at our facility for 31 nights in a row. Starting the morning after you check in, you will receive a single oral dose of the study drug or a placebo, which looks the same but has no active ingredient, once every 7 days, for a total of up to 5 doses. All doses will be given by mouth as either a liquid or tablet to swallow. Whether or not you receive placebo for any of the doses will be chosen at random. The first 4 doses will be given after an overnight fast without breakfast, and the last dose will be given with a standard breakfast.
Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.
This study requires you to stay at the PCRU for the entire duration of each inpatient stay unless you choose to withdraw. You can learn more about what to expect during your participation by browsing our FAQ section.
Required overnight stays
31 consecutive overnights
Long-term follow up
2 phone calls (~1 and 4 weeks after last dose)
How long is this study?
About 58 days
Compensation
Up to $14,150 upon completion of the study
All of the study procedures will be clearly explained to you during screening and can be viewed in the informed consent form.
We've updated the PCRU Loyalty Program!
We refreshed our Participant Loyalty Program with all-new unique tiered gifts for new and returning participants.
Interested in participating?
Complete and submit this form, and a Pfizer New Haven Clinical Research Unit (PCRU) representative will contact you.
You may also call 1-800-254-6398 and speak with a PCRU representative to learn more.
For Japanese language assistance only, please call 1-833-711-9984.
The personal data gathered here will be collected, processed, and maintained in a confidential manner. Your information will be stored in our research unit’s database. We may use this information to invite you to participate in current and future clinical studies at the PCRU. You will have full access to your records at the Pfizer New Haven Clinical Research Unit and the opportunity to correct them if necessary.